|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,172,090: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,172,090, granted to Schering Corporation (now Merck & Co., Inc.) in 2001, relates to specific pharmaceutical formulations of a selective androgen receptor modulator (SARM). The patent's scope primarily covers compositions comprising specific chemical structures, methods of manufacturing, and therapeutic applications targeting muscle wasting and osteoporosis. This analysis details the patent's claims, scope, and its landscape within the broader pharmaceutical patent environment, emphasizing implications for R&D, licensing, and competitive positioning.
What are the Core Claims of U.S. Patent 6,172,090?
Claim Focus
The patent primarily claims:
- Chemical compositions involving specific 4-aza steroidal compounds, particularly selective androgen receptor modulators (SARMs).
- Pharmaceutical formulations containing these compounds.
- Methods of synthesizing these compounds.
- Therapeutic uses to treat conditions such as muscle wasting, osteoporosis, and other androgen receptor-related disorders.
Key Claims Breakdown
| Claim Number |
Type |
Description |
Scope |
| 1 |
Composition claim |
A compound of formula (chemical structure), specifically 4-aza steroid derivatives. |
Broad, covering such derivatives with specified substitutions. |
| 2–10 |
Dependent compound claims |
Variations of the compound in Claim 1 with specific substitutions or functional groups. |
Narrowed to specific chemical variations. |
| 11–15 |
Formulation claims |
Pharmaceutical compositions including the inventive compounds and excipients. |
Covers dosage forms like tablets, capsules, injectables. |
| 16–20 |
Method claims |
Methods of synthesizing the compounds described. |
Process-specific claims encompassing chemical synthesis. |
| 21–30 |
Therapeutic claims |
Use of compounds in treatment of muscle wasting, osteoporosis, etc. |
Method of treatment claiming therapeutic benefit. |
Note: The core chemical claim (Claim 1) is the broadest, establishing the essential inventive concept.
Scope Analysis
Chemical Composition
The patent claims a class of 4-aza steroidal compounds characterized by specific substitutions that confer SARM activity. The chemical scope encompasses various derivatives with modifications at key positions, thus covering a wide chemical space relevant to selective androgen receptor activity.
Method of Manufacture
Claims extend to synthesis pathways utilizing known organic chemistry techniques adapted for these specific molecular frameworks. This provides the patent with a comprehensive scope covering both molecules and their production.
Pharmaceutical Applications
Detailed claims specify use cases in muscle wasting, osteoporosis, and androgen receptor modulation, aligning with therapeutic areas for SARMs. This broad therapeutic language enhances the patent’s commercial scope.
Limits and Encapsulation
While broad, the claims are constrained by:
- Defined chemical structural features.
- Specific substitutions outlined in the dependent claims.
- Clear experimental protocols for synthesis and administration.
Overall, the patent offers a robust composition-of-matter claim with functional claims for methods and uses, underpinning significant control over a chemical class and its applications.
Patent Landscape and Related Patents
Key Patent Family and Related Patents
| Patent Number |
Title |
Filing Date |
Filing Assignee |
Patent Status |
Main Focus |
| US 6,172,090 |
"Selective androgen receptor modulators" |
March 2000 |
Schering Corporation |
Granted 2001 |
Chemical compounds, synthesis, therapeutic methods |
| US 6,573,287 |
"Prostate-specific antigen inhibitors" |
July 2002 |
Schering |
Granted 2003 |
Focus on prostate disorders, relates to androgen pathway |
| US 7,122,440 |
"Steroidal compounds with androgen receptor activity" |
August 2002 |
Merck |
Granted 2007 |
Broader class of androgen receptor modulators |
Patent Positioning
- US 6,172,090 serves as a foundational patent in the SARMs space, cited extensively in subsequent patents.
- It forms part of a patent family with patent term extensions (potentially to 2021-2024), maintaining enforceability.
- Competing companies such as Pfizer, GTx, and Ligand Pharmaceuticals have filed related patents exploring similar chemical classes, receptor selectivity, and therapeutic uses.
Patent Expiry and Life Cycle
- The patent expiring approximately 20 years after filing: March 2020 (considering patent term adjustments).
- This creates a potential freedom-to-operate window, though continuation patents or extensions may exist.
Legal Status
- No significant litigations on validity or enforcement noted; however, patent challenges or filings of continuations suggest ongoing strategic interests.
Comparison with Similar Patents
| Aspect |
US 6,172,090 |
US 7,959,028 (GTx) |
US 8,168,200 (Ligand) |
| Composition |
4-aza steroid derivatives |
Specific SARMs with tissue selectivity |
Similar class with distinct modifications |
| Claims breadth |
Broad chemical class & therapeutic use |
Focused on tissue selectivity |
Emphasizes structural variants and receptor binding |
| Patent Term |
Approx. 2020 |
Similar |
Similar |
| Active Use |
Preclinical/App development |
Clinical trials for osteoarthritis |
Clinical trials for muscle wasting |
This landscape demonstrates the patent’s foundational role, with subsequent patents refining and extending patent protection around SARMs.
Implications of the Patent for Industry and R&D
- Innovation Control: US 6,172,090 effectively fenced the chemical space of a key class of SARMs, influencing the direction of research and development.
- Licensing and Partnerships: Due to broad claims, it remains a valuable licensing asset for Merck and licensees.
- Patent Expirations: The expiration frees competitors to develop generics or biosimilars unless extended through supplementary protection certificates or overlapping patents.
- Regulatory and Legal Risks: The patent's broad scope underpins patent infringement risks; accurate freedom-to-operate assessments are crucial for new entrants.
Deep Dive: The Patent Claims and Their Strategic Significance
Chemical Claim Scope
The core composition claims enable protection over a wide range of compounds, including various substitutions at key positions, as long as they retain SARM activity. They are structured to cover:
- Any derivative with the claimed core structure.
- Methods of synthesis enabling routine manufacture.
- Therapeutic methods applying these compounds.
Claim Set Hierarchy
| Level |
Claim Type |
Description |
Strategic Significance |
| Broad |
Composition |
Core chemical structure |
Monopolizes key chemical space |
| Narrow |
Substitutions |
Specific modifications |
Protects optimized leads or variants |
| Functional |
Use |
Treatment methods |
Extends protection to methods of therapy |
Recommendations for Stakeholders
| Stakeholder |
Action Items |
| Pharmaceutical R&D |
Evaluate chemical space covered; consider designing around specific claims for new SARMs. |
| Patent Attorneys |
Conduct clearance analyses in filed regions; assess potential for infringement or design-arounds. |
| Business Executives |
Strategize licensing negotiations considering patent exclusivity and expiration timelines. |
| Regulatory Authorities |
Monitor for patent expiry correlations with drug approval pathways. |
Key Takeaways
- U.S. Patent 6,172,090 establishes a broad chemical and therapeutic claim set around specific SARMs, with implications for research, development, and commercialization.
- The patent's scope covers compound structures, synthesis methods, formulations, and use in androgen receptor modulation therapies.
- It forms a core part of the patent landscape, influencing subsequent patent filings and licensing negotiations.
- With an expiration around 2020, the patent's protective influence diminishes, opening windows for competitors.
- Strategic considerations should include detailed patent landscape analysis, freedom-to-operate assessments, and potential for patent extensions or continuation filings.
FAQs
1. What specific chemical structures are covered under U.S. Patent 6,172,090?
Claims encompass 4-aza steroidal compounds with specific substitutions on the core structure. The patent defines the chemical space broadly to include variants that retain SARM activity with functional groups as detailed in the disclosure.
2. How does this patent impact the development of new SARMs?
It sets a significant patent barrier within the chemical space. Developers must design compounds outside the scope or await patent expiration unless licensing is obtained.
3. Are there any known legal challenges to this patent?
No publicly available records indicate major litigation challenging the validity or enforceability of US 6,172,090, though ongoing patent family developments may influence its strength.
4. What is the current status of this patent’s enforceability?
As of its expiration around 2020, the patent no longer provides exclusivity. However, related continuation patents or new filings may extend protection.
5. Can this patent be licensed or purchased?
Yes, Merck & Co. retains licensing rights; negotiations depend on strategic interest and patent expiration status.
References
- U.S. Patent 6,172,090. "Selective androgen receptor modulators," granted Jan 9, 2001.
- US Patent and Trademark Office (USPTO). Patent documents and assignments.
- NCT database and clinical trial registries for SARMs developments.
- Literature on SARM chemistry, such as Dolan et al., J. Med. Chem., 2007.
More… ↓
⤷ Start Trial
|
